

Human B7-H3/CD276 ELISA Kit | B7-H3/CD276 elisa kit

Human B7-H3/CD276 ELISA Kit

CATALOG #
AAA258422

REACTIVITY
Human


PRODUCT SYNONYMS

B7-H3/CD276; Human B7-H3/CD276 ELISA Kit; B7-H3 ELISA Kit; Human; CD276 molecule; 4lg-B7-H3 ELISA Kit; B7H3 ELISA Kit; B7RP-2 ELISA Kit; B7-H3/CD276 elisa kit

PRODUCT SPECIFICATIONS

Reactivity	Human
Specificity	This assay recognizes both recombinant and natural Human B7H3. The factors listed below were prepared at 50 ng/mL in dilution buffer and assayed for cross-reactivity. No cross-reactivity was observed.
Assay Type	Quantitative Sandwich
Samples	Serum and urine
Sensitivity	< 16.2 pg/mL
Intra-assay Precision	Three samples of known concentration were tested twenty times on one plate to assess intra-assay precision.
Inter-assay Precision	Three samples of known concentration were tested in five separate assays to assess inter-assay precision.

IMAGES



Standard Curve (Sample)

ADDITIONAL INFORMATION

Related Product Information for B7-H3/CD276 elisa kit	Background: B7-H3 is a member of the B7 family of immune regulatory ligands that is thought to attenuate peripheral immune responses through co-inhibition. It plays an important role in adaptive immune responses, and was shown to either promote or inhibit T-cell responses in various experimental systems. B7-H3 may play an important role in muscle-immune interactions, providing further evidence of the active role of muscle cells in local immunoregulatory processes. B7-H3 is a novel protein structurally related to the B7 family of ligands by the presence of a single set of immunoglobulin-V-like and immunoglobulin-C-like (VC) domains. Previous studies have correlated its overexpression with poor prognosis and decreased tumor-infiltrating lymphocytes in various carcinomas including uterine endometrioid carcinomas, and mounting evidence supports an immuno-inhibitory role in ovarian cancer prognosis. Recently, B7-H3 expression has been reported in several human cancers indicating an additional function of B7-H3 as a regulator of antitumor immunity. Principle of the Assay: The principle of this ELISA kit is based on the solid phase sandwich enzyme immunoassay technique. A monoclonal antibody specific for Human B7-H3 / CD276 has been pre-coated onto well plate strips. Standards and samples are added to the wells and Human B7-H3 / CD276 present in the sample is bound by the immobilized antibody. After incubation the wells are washed and a horseradish peroxidase conjugated anti-Human B7-H3 / CD276 antibody is added, producing an antibody-antigen-antibody "sandwich complex". Following a wash to remove any unbound antibody a TMB substrate solution is loaded and color develops in proportion to the amount of Human B7-H3 / CD276 bound. The reaction is stopped by the addition of a stop solution and the intensity of the color can be measured at 450 nm (See schematics below). Intended Uses: For the quantitative determination of Human B7-H3 / CD276 concentration in serum and urine.
References	Suh WK, et al. (2004) The immune regulatory protein B7-H3 promotes osteoblast differentiation and bone mineralization. Proc Natl Acad Sci U S A. 101(35): 12969-73. Waschbisch A, et al. (2008) Human muscle cells express the costimulatory molecule B7-H3, which modulates muscle-immune interactions. Arthritis Rheum. 58(11): 3600-8. Loos M, et al. (2010) B7-h3 and its role in antitumor immunity. Clin Dev Immunol. 2010: 683875. Zang X, et al. (2010) Tumor associated endothelial expression of B7-H3 predicts survival in ovarian carcinomas. Mod Pathol. 23(8): 1104-12. Sun J, et al. (2010) Clinical significance and regulation of the costimulatory molecule B7-H3 in human colorectal carcinoma. Cancer Immunol Immunother. 59(8): 1163-71.

For Research Use Only. Not for use in diagnostic or therapeutic procedures. Small volumes of product may become entrapped in the seal of the vial during shipment and storage; if necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the cap.